Breast Cancer Recurrence in the Small Intestine and Bone More Than 5 Years After Diagnosis

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Initial ER-positive, PR-positive, HER2-negative; metastatic lesion ER-negative, PR-negative, triple negative

Metastatic Site: small intestine, bone, right fallopian tube

More than 5 years after her December 2018 diagnosis, she was alive at 1-year follow-up after metastatic recurrence, with multiple bone metastases still present.

PubMed CentralRead more →

Stage IV ALK Lung Cancer: Amanda's Patient Story

Patient Info: Amanda, Female, Under 40 | Stage IV

Biomarkers: ALK-rearranged

Metastatic Site: pleural fluid, right clavicle lymph node

As of December 2024, Amanda had lived with Stage IV ALK-positive lung cancer for about 2 years and was taking 8 targeted-therapy pills daily.

The Patient StoryRead more →

Stage I Breast Cancer and a Separate Mixed Primary Liver Cancer in a 62-Year-Old Woman

Patient Info: Anonymized, Female, 60s | Stage I

Biomarkers: HER2/CerbB-2 positive

Postoperative pathology showed Stage I breast cancer, and the breast tumor did not progress.

PubMed CentralRead more →

ROS1-Positive Stage III Pulmonary Sarcomatoid Carcinoma With Complete Pathologic Response

Patient Info: Anonymized, male, 60s | Stage III

Biomarkers: ROS1 rearrangement; TP53 mutation; PD-L1 TPS 0%

No recurrence was seen for more than 30 months after surgery following a complete pathologic response.

PubMed CentralRead more →

Stage IV EGFR Non-Small Cell Lung Cancer: Filipe's Patient Story

Patient Info: Filipe, Male, Under 40 | Stage IV

Biomarkers: EGFR exon 19 deletion

Metastatic Site: brain, bone, left lung, kidney

As of November 2024, Filipe was living with ongoing Stage IV EGFR exon 19-mutated lung cancer after initial response to osimertinib, later progression and current amivantamab plus chemotherapy.

The Patient StoryRead more →

Breast carcinoma in remission with stable cancer-associated retinal findings during follow-up

Patient Info: Anonymized, Female, 70+

Biomarkers: Breast cancer marker details not fully reported. CRMP-5 antibody changed from positive to negative; anti-retinal antibodies were present.

The breast carcinoma was described as in remission, and visual acuity and visual fields remained stable without progressive visual loss across 3 years of ophthalmic follow-up.

PubMed CentralRead more →

HER2-positive squamous cell breast cancer in complete remission

Patient Info: Anonymized, Female, 40s | Stage II

Biomarkers: HER2-positive squamous cell breast cancer, ER/PR negative, PD-L1 negative

Clinical complete remission and survival beyond 4 years after mastectomy, AC-TH chemotherapy, and HER2-directed maintenance therapy for Stage IIA HER2-positive primary squamous cell breast cancer.

PubMed CentralRead more →

Lung Adenocarcinoma With Immune-Related Abdominal Inflammation and Later Bone Progression

Patient Info: Anonymized, male | Stage IV

Biomarkers: PD-L1 30%; KRAS G13X mutation; EGFR/ALK/ROS1 negative

Metastatic Site: bone

After several periods of response or stability, lymph-node progression recurred and bone progression was documented in July 2024. Another treatment line was being planned.

PubMed CentralRead more →

Stage 4 ALK-positive lung cancer: remission on lorlatinib

Patient Info: Anonymized, Male, Under 40 | Stage IV

Biomarkers: ALK-positive rearrangement; TTF-1-positive

Metastatic Site: bilateral lungs, mediastinal lymph nodes, bone, liver,…

Metastatic ALK-positive lung adenocarcinoma remained in radiologic and clinical remission on lorlatinib after CNS progression on earlier ALK-directed therapy and stereotactic radiosurgery.

PubMed CentralRead more →

Stage III lung adenocarcinoma: neoadjuvant brigatinib, surgery, no evidence of disease

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: Specific molecular alteration not stated in case 1 raw text; treated with brigatinib

No evidence of disease on PET-CT and brain MRI 27 months after surgery while receiving adjuvant brigatinib 90 mg daily.

PubMed CentralRead more →

Stage III EML4-ALK lung adenocarcinoma: brigatinib, surgery, no evidence of disease

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: EML4-ALK fusion rearrangement

No evidence of disease on PET-CT, with no brain metastases on MRI, after 32 months of adjuvant brigatinib following response and surgery.

PubMed CentralRead more →

Stage III EGFR-mutated lung adenocarcinoma: osimertinib and surgery

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: EGFR L858R; EGFR L861Q

No evidence of disease on PET-CT or brain MRI after 42 months of follow-up following neoadjuvant osimertinib and surgery.

PubMed CentralRead more →

Stage III EGFR exon 19-deleted lung adenocarcinoma: osimertinib and surgery

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: EGFR exon 19 deletion

No sign of metastasis on PET-CT or brain MRI after 24 months of follow-up following neoadjuvant osimertinib, left upper-lobe resection, and adjuvant osimertinib.

PubMed CentralRead more →

EGFR Lung Cancer: Jill's Survivor Story

Patient Info: Jill Feldman, Female, Under 40

Biomarkers: EGFR-positive

As of November 2024, Jill described living 15 years after her 2009 lung cancer diagnosis; current disease status and whether she remained on treatment were not clearly stated.

The Patient StoryRead more →

Metastatic Male Breast Cancer Responding to Abemaciclib and Letrozole

Patient Info: Anonymized, Male, 60s | Stage IV

Biomarkers: ER-positive, PR-negative, HER2-negative

Metastatic Site: soft tissue, distant lymph nodes, bone

The tumor and metastatic soft-tissue and lymph-node disease shrank markedly, with no progression on July 2024 imaging and good clinical condition in September 2024.

PubMed CentralRead more →

Stage III MET Exon 14-Positive Lung Adenocarcinoma Treated With Targeted Therapy Before Surgery

Patient Info: Anonymized, male, 60s | Stage I

Biomarkers: MET exon 14 skipping mutation; TP53 mutation

Postoperative pathology showed no involved lymph nodes and a lower pathologic Stage I group after treatment. No relapse was seen at the 6-month postoperative follow-up.

PubMed CentralRead more →

Severe Corneal Injury After Trastuzumab for Metastatic HER2-Positive Breast Cancer

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-positive

Metastatic Site: lungs, spine, left adrenal gland, calvarium, orbit,…

She was living with widespread metastatic breast cancer when trastuzumab was stopped because of severe eye toxicity.

PubMed CentralRead more →

Recurrent Lung Adenocarcinoma Complicated by a Tracheopericardial Fistula

Patient Info: Anonymized, male, 70+ | Stage II

Biomarkers: No gene mutations identified on postoperative testing

He died during the June 2024 admission, about 7½ years after his November 2016 lung-cancer diagnosis, after massive hemoptysis occurred in the setting of a tracheopericardial fistula and recurrent cancer.

PubMed CentralRead more →

Stage IV HR-Positive Invasive Ductal Carcinoma: Dee's Patient Story

Patient Info: Dee, Female, Under 40 | Stage IV

Biomarkers: ER-positive

Metastatic Site: Bones

As of October 2024, Dee was living with Stage IV metastatic ER-positive breast cancer after bone metastases were found in 2023 and had adapted to treatment with ribociclib.

The Patient StoryRead more →

Stage I Lung Adenocarcinoma With Later Kidney Metastases Responding to Osimertinib

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: EGFR L858R mutation; RB1 mutation; MAP3K1 mutation; PD-L1 negative

Metastatic Site: kidneys, peritoneal lymph nodes

Osimertinib produced a partial response within 6 weeks after metastatic recurrence in the kidneys. She remained alive and continued targeted treatment.

PubMed CentralRead more →

Metastatic Lung Cancer With Morphine-Induced Fever During Palliative Radiation

Patient Info: Anonymized, female, 50s | Stage IV

Metastatic Site: brain, bone

She remained on dacomitinib while receiving radiation for painful metastatic disease in 2022. After morphine was identified as the cause of recurrent fever and stopped, her symptoms resolved and she was discharged in satisfactory condition.

PubMed CentralRead more →

Stage IV EGFR-Mutant Lung Adenocarcinoma With Severe Respiratory Failure Responding to Almonertinib

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: EGFR exon 19 deletion

Within days of starting almonertinib, lung abnormalities improved enough for extubation. A March 2024 PET-CT showed satisfactory disease control with a partial response, and outpatient follow-up was ongoing with good performance status.

PubMed CentralRead more →

Stage IV HER2-Positive Invasive Ductal Carcinoma: Dee's Patient Story

Patient Info: Dee Doherty, Female, Under 40 | Stage IV

Biomarkers: Hormone-sensitive disease implied by letrozole and ovarian suppression; ER/PR/HER2 status not explicitly stated

Metastatic Site: bone

As of September 2024, Dee was living with Stage IV metastatic breast cancer. Her tumors had not shrunk, but disease was stable on ribociclib/Kisqali, letrozole, and ovarian suppression.

The Patient StoryRead more →

Stage III HER2-Positive Occult Breast Cancer With a Complete Response to Treatment

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: HER2-positive

Surgery after neoadjuvant treatment found no residual tumor in the breast or 20 examined lymph nodes, indicating a complete pathologic response; HER2-targeted therapy continued afterward.

PubMed CentralRead more →